Suppr超能文献

一种通过RACK1在体外抑制癌细胞生长的拮抗抗体。

An Antagonist Antibody That Inhibits Cancer Cell Growth In Vitro through RACK1.

作者信息

Kim Ji Hoe, Lee Eun Ji, Han Kyung Ho

机构信息

Department of Biological Sciences and Biotechnology, Hannam University, Daejeon 34054, Republic of Korea.

出版信息

Pharmaceuticals (Basel). 2024 Sep 30;17(10):1303. doi: 10.3390/ph17101303.

Abstract

BACKGROUND/OBJECTIVES: Our research introduces a novel screening method to identify antibodies that can suppress cell proliferation and induce apoptosis.

METHODS

By using an autocrine signaling system with lentivirus, we developed an antibody screening method based on FACS sorting assays and cell cycle analysis to inhibit tumor growth in vitro. This approach is particularly well suited for studying tumor suppressors. Inducing the G0 phase in tumor cells with specific antibodies may arrest their growth permanently or trigger apoptosis. The cell cycle is composed of tightly regulated phases for cell growth and division, with tumorigenesis or apoptosis occurring when these regulatory mechanisms fail.

RESULTS

In our study, we identified RACK1 as a key regulator of cancer cell growth. The H9 antibody against RACK1 selected from a human antibody library effectively suppressed cell proliferation by inhibiting RACK1 function.

CONCLUSIONS

These findings suggest that RACK1 plays a crucial role in tumor cell cycling and could represent a novel therapeutic target for cancer treatment. Although RACK1 is recognized as a significant target protein in various tumors, no commercial therapeutic agents currently exist. Our results suggest that the H9 antibody could be a promising candidate for the development of novel cancer therapies.

摘要

背景/目的:我们的研究引入了一种新型筛选方法,以鉴定能够抑制细胞增殖并诱导凋亡的抗体。

方法

通过使用带有慢病毒的自分泌信号系统,我们开发了一种基于荧光激活细胞分选(FACS)分析和细胞周期分析的抗体筛选方法,用于在体外抑制肿瘤生长。这种方法特别适合研究肿瘤抑制因子。用特异性抗体诱导肿瘤细胞进入G0期可能会使其生长永久停滞或触发凋亡。细胞周期由细胞生长和分裂的严格调控阶段组成,当这些调控机制失效时会发生肿瘤发生或凋亡。

结果

在我们的研究中,我们确定RACK1是癌细胞生长的关键调节因子。从人抗体库中筛选出的针对RACK1的H9抗体通过抑制RACK1功能有效抑制了细胞增殖。

结论

这些发现表明RACK1在肿瘤细胞周期中起关键作用,可能代表癌症治疗的新靶点。尽管RACK1在各种肿瘤中被认为是重要的靶蛋白,但目前尚无商业治疗药物。我们的结果表明,H9抗体可能是开发新型癌症疗法的有前途的候选药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d8a/11510629/6518b62e2ff7/pharmaceuticals-17-01303-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验